Sanofi, Regeneron anti-PD-1 mAb gets Priority Review

Sanofi (Euronext:SAN; NYSE:SNY) and partner Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said FDA accepted and granted Priority Review to a BLA for cemiplimab (REGN2810; SAR439684) to treat metastatic cutaneous squamous cell carcinoma (CSCC) or advanced CSCC in patients who are not candidates for surgery. The PDUFA date is Oct. 28.

The partners are developing cemiplimab jointly under a 2015 deal...